Discovery of Tumor, Treatment Response, and Systems-based EVP Signatures

作为一名执业放射肿瘤学家，我试图将我的实验室和临床工作整合到一个有凝聚力的转化研究项目中，我把我的临床实践集中在转移性癌症患者的护理上，对他们来说，放射可能是有益的。在过去的一年里，我在NCI放射肿瘤学分会创建了颅外晚期恶性肿瘤治疗小组（TEAM），我们正在制定旨在改善晚期恶性肿瘤患者评估和治疗的方案。我在TEAM小组的一个主要工作重点是液体活检，目前的一个主要研究目标是确定液体活检或生物流体EVP谱与治疗反应之间的关系。该项目的转化研究工作遵循双管齐下的方法：1)与NIH的医学和外科肿瘤学同事合作，研究evp作为肿瘤状态的生物标志物，作为这些合作者现有协议的一部分；2)开发新的临床协议，以更有凝聚力和信息丰富的方式从患者群体中获取信息和样本。这两种方法都得到了CCR临床转化任务的支持，并为转化纳米生物学部门正在进行的EVP谱研究的基础科学工作提供了支持。

As a practicing radiation oncologist, seeking to integrate my laboratory and clinical efforts into a cohesive translational research program, I have focused my clinical practice on the care of patients with metastatic cancers, for whom radiation may be beneficial. In the past year, I created the Treatment of Extra-cranial Advanced Malignancies (TEAM) group in the NCI Radiation Oncology Branch, and we are developing protocols designed to improve the assessment and treatment of patients with advanced malignancies. A major focus of my work with the TEAM group is liquid biopsies, and a major research aim currently is to determine what liquid biopsy or biofluid EVP profiles correlate with responses to treatment. The translational research efforts of this project are following a two-pronged approach: 1) collaborating with medical and surgical oncology colleagues at NIH to investigate EVPs as biomarkers for tumor status as part of those collaborators' existing protocols, and 2) developing new clinical protocols to capture information and samples from this patient population in a more cohesive and informative manner. Both of these approaches are supported by and provide support to the CCR's clinical translational mission and the basic scientific work ongoing in the Translational Nanobiology Section for the study of EVP repertoires.